Rohto Pharmaceutical (4527) Q1 2026 earnings summary

Executive summary

• Q1 2025 sales rose 19.9% year-over-year to 81,964 million yen, driven by strong domestic and overseas demand, especially in Asia and Europe, and recent acquisitions.

• Operating income slightly decreased by 0.8% year-over-year to 11,699 million yen due to higher COGS and SG&A expenses.

• Ordinary income surged 31.4% year-over-year to 16,127 million yen, and profit attributable to owners of parent increased 38.7% to 11,769 million yen, mainly from higher dividend income.

• Full-year 2025 earnings forecast was revised upward, anticipating record-high sales and increased profit despite yen appreciation.

Financial highlights

• Gross profit for Q1 2025 was 45,852 million yen (up 17.3% year-over-year), with a gross margin of 55.9%.

• EBITDA increased 12.5% year-over-year to 15,786 million yen, with an EBITDA margin of 19.3%.

• Net income per share was 52.09 yen, up from 37.18 year-over-year.

• Comprehensive income fell to 7,769 million yen from 16,071 million year-over-year, mainly due to negative foreign currency translation adjustments.

• Net assets increased to 284,147 million yen, with a capital adequacy ratio of 62.2%.

Outlook and guidance

• Full-year 2025 sales forecast revised upward to 334.5 billion yen (+8.4% year-over-year), with operating income at 39 billion yen (+2.0%).

• Ordinary income and profit attributable to owners of parent revised upward by 2.5 billion yen and 400 million yen, respectively, versus initial plan.

• Dividend forecast for the year is 42 yen per share, up from 36 yen in the previous year, with a payout ratio of 30.1%.

• Asia and Europe expected to drive growth; Americas and Japan face headwinds from yen appreciation and subsidiary performance.